Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTMAB-16 in Pulmonary Sarcoidosis
NCT05890729Phase 2Active, not recruiting
- Sponsor
- Xentria
- Start
- Nov 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of xtmab-16 in pulmonary sarcoidosis, sponsored by Xentria. Started Nov 2023; status: active, not recruiting.
02
Drugs
xtmab-16
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT05890729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890729.